Open AccessImprovement of Clinical Symptoms and Gut Microbiome After Fecal Microbiota Transplantation: A Case Study of a 106-Year-Old Man with MODS
Author(s) -
Jingyun Fang,
Jiayu Yin,
Qinghong Liu,
Xiangyi Yang,
Xuesong He,
Shengzhou Wang,
Fan Min,
Mohammed Alnaggar,
Jingxu Wang,
Zhaoqun Deng,
Yuanfei Liu
Publication year - 2022
Publication title -
proceedings of anticancer research
Language(s) - English
Resource type - Journals
eISSN - 2208-3553
pISSN - 2208-3545
DOI - 10.26689/par.v6i1.2840
Subject(s) - feces , microbiome , fecal bacteriotherapy , dysbiosis , medicine , diarrhea , immunology , gut flora , transplantation , clostridium difficile , gastroenterology , biology , microbiology and biotechnology , bioinformatics , antibiotics
Fecal microbiota transplantation (FMT) has been used in a wide variety of diseases. Many researchers hypothesize that the dysbiosis of intestinal microbiota plays an important role in the development of gut-derived infections; thus, FMT is a potential therapeutic target against multiple organ dysfunction syndrome (MODS). A 106-year-old male patient was initially diagnosed with cerebral infarction and pulmonary infection. During the course of hospitalization, the patient developed MODS. The patient received a single nasogastric infusion of sterile-filtered, pathogen-free feces from a healthy donor. Fecal samples were collected every two days post-infusion to monitor changes in the microbiota composition in response to treatment. After FMT, MODS and severe diarrhea were alleviated; the patient’s fecal microbiome diversity resembled that of the healthy donor’s fecal microbiome; moreover, his clinical symptoms improved remarkably with the changes in fecal microbiome. Additionally, no observable side effects were noted during FMT treatment. These findings warrant further investigation of FMT as a putative new therapy for treating microbiota-related diseases, such as MODS.